Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: Implications for combination therapy for melanoma brain metastases

Shruthi Vaidhyanathan, Rajendar K. Mittapalli, Jann N Sarkaria, William F. Elmquist

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Brain metastases are a major cause of mortality in patients with advanced melanoma. Adequate brain distribution of targeted agents for melanoma will be critical for treatment success. Recently, improvement in overall survival led to US Food and Drug Administration (FDA) approval of the v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, vemurafenib and dabrafenib, and the mitogen-activated protein kinase kinase-1 (MEK)-1/2 inhibitor, trametinib. However, brain metastases and emergence of resistance remain a significant problem. MEK-1/2 is downstream of BRAF in the mitogen-activated protein kinase (MAPK) signaling pathway, making it an attractive target to combat resistance. The recently approved combination of dabrafenib and trametinib has shown improvement in progression-free survival; however, adequate brain distribution of both compounds is required to effectively treat brainmetastases. In previous studies, we found limited brain distribution of dabrafenib. The purpose of the current study was to investigate factors influencing the brain distribution of trametinib. In vitro studies indicated that trametinib is a substrate for both P-glycoprotein (P-gp) and Bcrp, efflux transporters found at the blood-brain barrier. In vivo studies in transgenic mouse models confirmed that P-gp plays an important role in restricting brain distribution of trametinib. The brain-to-plasma partition coefficient (AUCbrain/AUCplasma) was approximately 5-fold higher in Mdr1a/b(-/-) (P-gp knockout) and Mdr1a/b(-/-)Bcrp1(-/-)(triple knockout) mice when compared with wild-type and Bcrp1(-/-)(Bcrp knockout) mice. The brain distribution of trametinib was similar between the wild-type and Bcrp knockout mice. These results show that P-gp plays an important role in limiting brain distribution of trametinib and may have important implications for use of trametinib as single agent or in combination therapy for treatment of melanoma brain metastases.

Original languageEnglish (US)
Pages (from-to)1292-1300
Number of pages9
JournalDrug Metabolism and Disposition
Volume42
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Melanoma
Neoplasm Metastasis
Brain
P-Glycoprotein
Knockout Mice
Therapeutics
MAP Kinase Kinase 1
Drug Approval
trametinib
Mitogen-Activated Protein Kinases
Blood-Brain Barrier
Oncogenes
Sarcoma
Transgenic Mice
Disease-Free Survival
Food

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Medicine(all)

Cite this

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor : Implications for combination therapy for melanoma brain metastases. / Vaidhyanathan, Shruthi; Mittapalli, Rajendar K.; Sarkaria, Jann N; Elmquist, William F.

In: Drug Metabolism and Disposition, Vol. 42, No. 8, 2014, p. 1292-1300.

Research output: Contribution to journalArticle

@article{3c496cb3e2694f7bafd1f90a70e72c53,
title = "Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: Implications for combination therapy for melanoma brain metastases",
abstract = "Brain metastases are a major cause of mortality in patients with advanced melanoma. Adequate brain distribution of targeted agents for melanoma will be critical for treatment success. Recently, improvement in overall survival led to US Food and Drug Administration (FDA) approval of the v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, vemurafenib and dabrafenib, and the mitogen-activated protein kinase kinase-1 (MEK)-1/2 inhibitor, trametinib. However, brain metastases and emergence of resistance remain a significant problem. MEK-1/2 is downstream of BRAF in the mitogen-activated protein kinase (MAPK) signaling pathway, making it an attractive target to combat resistance. The recently approved combination of dabrafenib and trametinib has shown improvement in progression-free survival; however, adequate brain distribution of both compounds is required to effectively treat brainmetastases. In previous studies, we found limited brain distribution of dabrafenib. The purpose of the current study was to investigate factors influencing the brain distribution of trametinib. In vitro studies indicated that trametinib is a substrate for both P-glycoprotein (P-gp) and Bcrp, efflux transporters found at the blood-brain barrier. In vivo studies in transgenic mouse models confirmed that P-gp plays an important role in restricting brain distribution of trametinib. The brain-to-plasma partition coefficient (AUCbrain/AUCplasma) was approximately 5-fold higher in Mdr1a/b(-/-) (P-gp knockout) and Mdr1a/b(-/-)Bcrp1(-/-)(triple knockout) mice when compared with wild-type and Bcrp1(-/-)(Bcrp knockout) mice. The brain distribution of trametinib was similar between the wild-type and Bcrp knockout mice. These results show that P-gp plays an important role in limiting brain distribution of trametinib and may have important implications for use of trametinib as single agent or in combination therapy for treatment of melanoma brain metastases.",
author = "Shruthi Vaidhyanathan and Mittapalli, {Rajendar K.} and Sarkaria, {Jann N} and Elmquist, {William F.}",
year = "2014",
doi = "10.1124/dmd.114.058339",
language = "English (US)",
volume = "42",
pages = "1292--1300",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "8",

}

TY - JOUR

T1 - Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor

T2 - Implications for combination therapy for melanoma brain metastases

AU - Vaidhyanathan, Shruthi

AU - Mittapalli, Rajendar K.

AU - Sarkaria, Jann N

AU - Elmquist, William F.

PY - 2014

Y1 - 2014

N2 - Brain metastases are a major cause of mortality in patients with advanced melanoma. Adequate brain distribution of targeted agents for melanoma will be critical for treatment success. Recently, improvement in overall survival led to US Food and Drug Administration (FDA) approval of the v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, vemurafenib and dabrafenib, and the mitogen-activated protein kinase kinase-1 (MEK)-1/2 inhibitor, trametinib. However, brain metastases and emergence of resistance remain a significant problem. MEK-1/2 is downstream of BRAF in the mitogen-activated protein kinase (MAPK) signaling pathway, making it an attractive target to combat resistance. The recently approved combination of dabrafenib and trametinib has shown improvement in progression-free survival; however, adequate brain distribution of both compounds is required to effectively treat brainmetastases. In previous studies, we found limited brain distribution of dabrafenib. The purpose of the current study was to investigate factors influencing the brain distribution of trametinib. In vitro studies indicated that trametinib is a substrate for both P-glycoprotein (P-gp) and Bcrp, efflux transporters found at the blood-brain barrier. In vivo studies in transgenic mouse models confirmed that P-gp plays an important role in restricting brain distribution of trametinib. The brain-to-plasma partition coefficient (AUCbrain/AUCplasma) was approximately 5-fold higher in Mdr1a/b(-/-) (P-gp knockout) and Mdr1a/b(-/-)Bcrp1(-/-)(triple knockout) mice when compared with wild-type and Bcrp1(-/-)(Bcrp knockout) mice. The brain distribution of trametinib was similar between the wild-type and Bcrp knockout mice. These results show that P-gp plays an important role in limiting brain distribution of trametinib and may have important implications for use of trametinib as single agent or in combination therapy for treatment of melanoma brain metastases.

AB - Brain metastases are a major cause of mortality in patients with advanced melanoma. Adequate brain distribution of targeted agents for melanoma will be critical for treatment success. Recently, improvement in overall survival led to US Food and Drug Administration (FDA) approval of the v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, vemurafenib and dabrafenib, and the mitogen-activated protein kinase kinase-1 (MEK)-1/2 inhibitor, trametinib. However, brain metastases and emergence of resistance remain a significant problem. MEK-1/2 is downstream of BRAF in the mitogen-activated protein kinase (MAPK) signaling pathway, making it an attractive target to combat resistance. The recently approved combination of dabrafenib and trametinib has shown improvement in progression-free survival; however, adequate brain distribution of both compounds is required to effectively treat brainmetastases. In previous studies, we found limited brain distribution of dabrafenib. The purpose of the current study was to investigate factors influencing the brain distribution of trametinib. In vitro studies indicated that trametinib is a substrate for both P-glycoprotein (P-gp) and Bcrp, efflux transporters found at the blood-brain barrier. In vivo studies in transgenic mouse models confirmed that P-gp plays an important role in restricting brain distribution of trametinib. The brain-to-plasma partition coefficient (AUCbrain/AUCplasma) was approximately 5-fold higher in Mdr1a/b(-/-) (P-gp knockout) and Mdr1a/b(-/-)Bcrp1(-/-)(triple knockout) mice when compared with wild-type and Bcrp1(-/-)(Bcrp knockout) mice. The brain distribution of trametinib was similar between the wild-type and Bcrp knockout mice. These results show that P-gp plays an important role in limiting brain distribution of trametinib and may have important implications for use of trametinib as single agent or in combination therapy for treatment of melanoma brain metastases.

UR - http://www.scopus.com/inward/record.url?scp=84904191651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904191651&partnerID=8YFLogxK

U2 - 10.1124/dmd.114.058339

DO - 10.1124/dmd.114.058339

M3 - Article

C2 - 24875464

AN - SCOPUS:84904191651

VL - 42

SP - 1292

EP - 1300

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 8

ER -